Aratana Therapeutics raises $15m in Series B financing

Wednesday, December 7, 2011 10:01 AM

Aratana Therapeutics has closed a $15 million Series B financing, bringing the total capital raised since Aratana was launched earlier this year to $31 million.

In addition to Aratana's Series A investors – MPM Capital, Avalon Ventures and Cultivian Ventures – new investors include the Ewing Marion Kauffman Foundation and others.

The proceeds from the Series B financing will be used to expand the pipeline of innovative products that the company has already acquired. The additional resources allow for a more aggressive approach to in-license and develop novel medicines for dogs and cats.

"We are extremely pleased that the investment community has responded so positively to our unique approach to veterinary drug development and our focus on delivering innovative, leading-edge products to meet previously unmet or under-served needs in companion animal medicine," said Dr. Linda Rhodes, CEO of Aratana Therapeutics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs